866-997-4948(US-Canada Toll Free)

Graves Diseases - Pipeline Review, H2 2016

Published By :

Global Markets Direct

Published Date : Dec 2016

Category :

Pharmaceutical

No. of Pages : 37 Pages

Graves Diseases - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Graves Diseases Pipeline Review, H2 2016, provides an overview of the Graves Diseases (Hormonal Disorders) pipeline landscape.

Graves' disease is an immune system disorder that results in the overproduction of thyroid hormones (hyperthyroidism). Symptoms include anxiety, weight loss, change in menstrual cycles, erectile dysfunction, bulging eyes and irregular heartbeat. Risk factors include family history, age, autoimmune disorders, smoking and pregnancy. Treatment includes anti-thyroid medications, beta blockers and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Graves Diseases Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Graves Diseases (Hormonal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Graves Diseases (Hormonal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Graves Diseases and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 2 and 1 respectively.

Graves Diseases (Hormonal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Graves Diseases (Hormonal Disorders).
- The pipeline guide reviews pipeline therapeutics for Graves Diseases (Hormonal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Graves Diseases (Hormonal Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Graves Diseases (Hormonal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Graves Diseases (Hormonal Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Graves Diseases (Hormonal Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Graves Diseases (Hormonal Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Graves Diseases Overview 6
Therapeutics Development 7
Pipeline Products for Graves Diseases - Overview 7
Graves Diseases - Therapeutics under Development by Companies 8
Graves Diseases - Pipeline Products Glance 9
Clinical Stage Products 9
Early Stage Products 10
Graves Diseases - Products under Development by Companies 11
Graves Diseases - Companies Involved in Therapeutics Development 12
Apitope International NV 12
Nova Therapeutics LLC 13
Novartis AG 14
Omeros Corp 15
Rodos BioTarget GmbH 16
Graves Diseases - Therapeutics Assessment 17
Assessment by Monotherapy Products 17
Assessment by Target 18
Assessment by Mechanism of Action 20
Assessment by Route of Administration 22
Assessment by Molecule Type 24
Drug Profiles 26
ATXGD-59 - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
CFZ-533 - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
K-170 - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
NV-02 - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
Protein for Graves Diseases - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
Small Molecule to Target GPR174 for Immunology, Neurology and Oncology - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
Graves Diseases - Dormant Projects 33
Graves Diseases - Product Development Milestones 34
Featured News & Press Releases 34
Oct 26, 2016: Apitope Announces Enrolment of First Patient in Phase I Trial of ATX-GD-59 for the Treatment of Graves Disease 34
Jun 19, 2014: Apitope Progresses Graves' Disease Treatment 34
Appendix 36
Methodology 36
Coverage 36
Secondary Research 36
Primary Research 36
Expert Panel Validation 36
Contact Us 36
Disclaimer 37

List of Tables
Number of Products under Development for Graves Diseases, H2 2016 7
Number of Products under Development by Companies, H2 2016 8
Comparative Analysis by Clinical Stage Development, H2 2016 9
Products under Development by Companies, H2 2016 11
Graves Diseases - Pipeline by Apitope International NV, H2 2016 12
Graves Diseases - Pipeline by Nova Therapeutics LLC, H2 2016 13
Graves Diseases - Pipeline by Novartis AG, H2 2016 14
Graves Diseases - Pipeline by Omeros Corp, H2 2016 15
Graves Diseases - Pipeline by Rodos BioTarget GmbH, H2 2016 16
Assessment by Monotherapy Products, H2 2016 17
Number of Products by Stage and Target, H2 2016 19
Number of Products by Stage and Mechanism of Action, H2 2016 21
Number of Products by Stage and Route of Administration, H2 2016 23
Number of Products by Stage and Molecule Type, H2 2016 25
Graves Diseases - Dormant Projects, H2 2016 33

List of Figures
Number of Products under Development for Graves Diseases, H2 2016 7
Number of Products under Development by Companies, H2 2016 8
Comparative Analysis by Clinical Stage Development, H2 2016 9
Comparative Analysis by Early Stage Products, H2 2016 10
Assessment by Monotherapy Products, H2 2016 17
Number of Products by Targets, H2 2016 18
Number of Products by Stage and Targets, H2 2016 18
Number of Products by Mechanism of Actions, H2 2016 20
Number of Products by Stage and Mechanism of Actions, H2 2016 20
Number of Products by Routes of Administration, H2 2016 22
Number of Products by Stage and Routes of Administration, H2 2016 22
Number of Products by Molecule Types, H2 2016 24
Number of Products by Stage and Molecule Types, H2 2016 24

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *